Description: Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Home Page: www.affimed.com
AFMD Technical Analysis
Technologiepark
Heidelberg,
69120
Germany
Phone:
49 6221 6743 60
Officers
| Name | Title |
|---|---|
| Dr. Adi Hoess | CEO, MD & Member of Management Board |
| Mr. Angus W. Smith | CFO & Member of Management Board |
| Dr. Wolfgang Fischer | MD, COO & Member of Management Board |
| Ms. Denise Mueller | Chief Bus. Officer & Member of Management Board |
| Dr. Andreas Harstrick M.D. | Chief Medical Officer & Member of Management Board |
| Dr. Arndt J. G. Schottelius M.D., Ph.D. | Chief Scientific Officer & Member of Management Board |
| Prof. Melvyn Little | Founder & Consultant |
| Mr. Michael Wolf | Head of Fin. & Admin. |
| Mr. Alexander Fudukidis | Head of Investor Relations |
| Dr. Uwe Reusch | Head of Cell Culture |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9232 |
| Price-to-Sales TTM: | 3.7958 |
| IPO Date: | 2014-09-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 197 |